Please read and agree to the terms and conditions of this site.
@xconomy.com 3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com 4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com 4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com 5 years ago
Qpex Biopharma Launches with $33M to Tackle Drug-Resistant Infections
@xconomy.com 5 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines